|
Real-time Estimate
Cboe BZX
10:58:05 02/09/2026 pm IST
|
5-day change | 1st Jan Change | ||
| 148.21 USD | -3.93% |
|
-0.56% | +404.64% |
| 01/09 | GSK Moves mRNA Flu Vaccine Candidate to Late-Stage Trial | DJ |
| 01/09 | GSK to advance mRNA flu vaccine to late-stage trial | RE |
| Market Cap | 6.16TCr 5.31TCr 5.01TCr 4.56TCr 8.52TCr 5,81800Cr 8.59TCr 59TCr 23TCr 2,97500Cr 23TCr 23TCr 9,77200Cr | P/E 2026 * |
-18.1x | P/E 2027 * | -31.4x |
|---|---|---|---|---|---|
| Enterprise Value | 5.79TCr 5TCr 4.71TCr 4.29TCr 8.02TCr 5,47300Cr 8.08TCr 56TCr 22TCr 2,79800Cr 22TCr 21TCr 9,19300Cr | EV / Sales 2026 * |
27.6x | EV / Sales 2027 * | 24.3x |
| Free-Float |
92.68% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript : Moderna, Inc.
| 1 day | -4.29% | ||
| 1 week | -1.64% | ||
| Current month | +4.89% | ||
| 1 month | +166.96% | ||
| 3 months | +222.52% | ||
| 6 months | +178.55% | ||
| Current year | +399.15% |
| 1 week | 133.33 |  | 156.42 |
| 1 month | 52.66 | | 176.66 |
| Current year | 29.81 | | 176.66 |
| 1 year | 22.28 | | 176.66 |
| 3 years | 22.28 | | 176.66 |
| 5 years | 22.28 | | 464.85 |
| 10 years | 11.54 | | 497.49 |
| Manager | Title | Age | Since |
|---|---|---|---|
Stéphane Bancel
CEO | Chief Executive Officer | 54 | 01/03/2011 |
James Mock
DFI | Director of Finance/CFO | 49 | 06/09/2022 |
Stephen Hoge
PSD | President | 50 | 01/11/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Noubar Afeyan
CHM | Chairman | 63 | 01/02/2012 |
Stéphane Bancel
BRD | Director/Board Member | 54 | 01/03/2011 |
Francois Nader
BRD | Director/Board Member | 69 | 11/12/2019 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 28/08/26 | Exercice | Chief Financial Officer | 818 | 0.0002% | ||
| 28/08/26 | Exercice | Chairperson | 1,518 | 0.0004% | ||
| 28/08/26 | Exercice | General Counsel | 818 | 0.0002% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -4.34% | -1.64% | +508.52% | +34.60% | 6.16TCr | |
| +2.66% | +3.01% | +45.23% | +1.99% | 8.23TCr | |
| +0.89% | +0.12% | -17.32% | -35.39% | 5.9TCr | |
| -1.25% | -5.30% | -1.98% | +33.18% | 5.12TCr | |
| +0.92% | -0.23% | +11.50% | +169.82% | 4.83TCr | |
| +3.57% | +0.55% | +59.20% | -16.52% | 3.19TCr | |
| +1.94% | -1.01% | +47.51% | +100.43% | 2.53TCr | |
| +0.20% | +1.70% | -3.42% | +190.03% | 2.26TCr | |
| -0.52% | -1.98% | +65.45% | +110.84% | 1.66TCr | |
| -0.83% | -2.29% | -14.71% | +786.97% | 1.53TCr | |
| Average | +0.33% | -2.66% | +70.00% | +137.60% | 4.14TCr | |
| Weighted average by Cap. | +0.32% | -2.82% | +92.61% | +73.10% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 209.66Cr 180.88Cr 170.39Cr 155.25Cr 290.18Cr 20TCr 292.35Cr 2.02TCr 782.88Cr 10TCr 787.31Cr 770.09Cr 33TCr | 244.34Cr 210.79Cr 198.57Cr 180.92Cr 338.17Cr 23TCr 340.71Cr 2.35TCr 912.37Cr 12TCr 917.53Cr 897.47Cr 39TCr |
| Net income | -331.27Cr -285.78Cr -269.21Cr -245.29Cr -458.48Cr -31TCr -461.92Cr -3.19TCr -1.24TCr -16TCr -1.24TCr -1.22TCr -53TCr | -194.11Cr -167.46Cr -157.75Cr -143.73Cr -268.65Cr -18TCr -270.67Cr -1.87TCr -724.8Cr -9.37TCr -728.9Cr -712.96Cr -31TCr |
| Net Debt | -364.91Cr -314.8Cr -296.55Cr -270.2Cr -505.04Cr -34TCr -508.83Cr -3.51TCr -1.36TCr -18TCr -1.37TCr -1.34TCr -58TCr | -219.36Cr -189.24Cr -178.27Cr -162.43Cr -303.6Cr -21TCr -305.88Cr -2.11TCr -819.1Cr -11TCr -823.73Cr -805.72Cr -35TCr |
| Date | Price | Change | Volume |
|---|---|---|---|
| 02/26/02 | $149.38 | -3.17% | 1,04,09,901 |
| 01/26/01 | $154.27 | +9.93% | 2,58,31,743 |
| 31/26/31 | $140.34 | +1.70% | 1,85,70,704 |
| 28/26/28 | $137.99 | -3.35% | 2,58,20,563 |
| 27/26/27 | $142.77 | -4.60% | 2,49,93,236 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- MRNA Stock
Select your edition
All financial news and data tailored to specific country editions
